

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		C mplete if Known	
O I P INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>SEP 23 2002 (use as many sheets as necessary)</small>		Application Number	10/044,538
		Filing Date	January 10, 2002
		First Named Inventor	Abraham J. Domb
		Group Art Unit	1636
		Examiner Name	
		Attorney Docket Number	PG 100
Sheet	1	of	2

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				
		PCT	WO-95/30020		Immuno-Designed Molecules	12-09-1995		
GC		PCT	WO 97/46223		Genzyme Corporation	12-11-1997		
		PCT	WO 98/27209		Emory University	06-25-1998		
		PCT	WO 01/07486		Polygene, Ltd.	02-01-2001		
GR		EP	0 370 810		Nippon Oil and Fats Co.	11-23-1989		

**Examine
Signature**

G. K. B. L.

Date Considered
4/5/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/044,538
		Filing Date	January 10, 2002
		First Named Inventor	Abraham J. Domb
		Group Art Unit	1636
		Examiner Name	
Sheet	of	Attorney Docket Number	PG 100

RECEIVED

SEP 25 2002

TECH CENTER

1600/29

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GK		BYK & SCHERMAN <i>Exp. Opin. Ther.</i> 8(9): 1125-1141 (1998).	
		DOMB, et al., "Polymers in gene therapy," in <i>Frontiers in Biological Polymer Applications</i> (Ottenbrite, ed.) Technomic: Lancaster, Vol. 2, pp. 1-16 (1999).	
		KIELY, et al., "Hydroxylated nylons based on unprotected esterified D-glucaric acid by simple condensation reactions," <i>J. Am. Chem. Soc.</i> 116: 571-578 (1994).	
		LEDLEY, "Nonviral gene therapy: The promise of genes as pharmaceutical products," <i>Human Gene Therapy</i> 6: 1129-1144 (1995).	
		LEE, et al., "Self aggregates of hydrophobically modified chitosan for DNA delivery," <i>Proceed Intl. Symp. Control. Rel. Bioact. Matter</i> 24: 651-652 (1997).	
		MAO, et al., "DNA-chitosan nanospheres: derivitization and storage stability," <i>Proc. Intl. Symp. Control Rel. Bioact. Matter</i> 24: 671-672 (1997).	
		RICHARDSON, et al., "Evaluation of highly purified chitosan as a potential gene delivery vector," <i>Proceed Intl. Symp. Control Rel. Bioact. Matter</i> 24: 649-650 (1997).	
		TAKAKURA, et al., "Control of pharmaceutical properties of soybean tyrosine inhibitor by conjugation with dextran 1: synthesis and characterization," <i>J. Pharm. Sci.</i> 78(2): 117-121 (1999).	
		TRECO & SELDEN, "Non viral gene therapy," <i>Molec. Med. Today</i> 1(7):299-348 (1995).	
		WALSH, et al., "Combination of drug and gene delivery by gelatin nanospheres for the treatment of cystic fibrosis," <i>Proc. Intl. Sym. Control. Rel. Bioact. Mater.</i> 24: 75-76 (1997).	
GK		YAMAOKA, et al., "Effect of cation content of polycation-type gene carriers on <i>in vitro</i> gene transfer," <i>Chemistry Letters</i> , 1171-1172 (1998).	

Examiner's Signature	G.Kris	Date Considered	4/5/03
----------------------	--------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

SEP 27 2002